Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

84.60EUR
9:06pm IST
Price Change (% chg)

€-0.30 (-0.35%)
Prev Close
€84.90
Open
€84.60
Day's High
€84.89
Day's Low
€84.02
Volume
2,561,457
Avg. Vol
3,158,140
52-wk High
€89.95
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.56
Market Cap (Mil.): €112,660.20
Shares Outstanding (Mil.): 1,326.97
Dividend: 2.80
Yield (%): 3.30

Financials

  SASY.PA Industry Sector
P/E (TTM): 27.35 33.08 33.86
EPS (TTM): 3.10 -- --
ROI: 5.31 18.26 17.52
ROE: 7.69 18.93 18.34
Search Stocks

Actavis, Sanofi among bidders for Omega Pharma: Bloomberg

- Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV [COUCKO.UL], Bloomberg reported, citing people familiar with the matter.

21 Oct 2014

Actavis, Sanofi among bidders for Omega Pharma - Bloomberg

Oct 20 - Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV, Bloomberg reported, citing people familiar with the matter.

21 Oct 2014

Sanofi, Regeneron start Phase 3 trial of dupilumab in eczema

PARIS, Oct 20 - French drugmaker Sanofi and its U.S. partner Regeneron said on Monday they had started a Phase III clinical study of their experimental drug dupilumab in patients with atopic dermatitis.

20 Oct 2014

BRIEF-Ab-Biotics, Sanofi to launch a gastro-pediatric drug in Spain

* Said on Thursday it reached agreement with French Sanofi to launch a gastro-pediatric drug in Spain

17 Oct 2014

Belgium's Galapagos hires Sanofi Europe exec as new CFO

BRUSSELS, Oct 15 - Belgian biotech group Galapagos said on Wednesday that it had hired Bart Filius, vice president of Sanofi Europe, as its new chief financial officer.

15 Oct 2014

Geographic split likely for GSK mature drugs sale: sources

LONDON - GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.

14 Oct 2014

Geographic split likely for GSK mature drugs sale -sources

LONDON, Oct 14 - GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.

14 Oct 2014

Sanofi's Rotavirus vaccine enters late-stage trials

PARIS - French drugmaker Sanofi said on Tuesday an investigational vaccine designed by its Shantha Biotechnics unit to protect young children from severe diarrhea had entered late-stage clinical trials in India.

14 Oct 2014

Sanofi's Rotavirus vaccine enters late-stage trials

PARIS, Oct 14 - French drugmaker Sanofi said on Tuesday an investigational vaccine designed by its Shantha Biotechnics unit to protect young children from severe diarrhoea had entered late-stage clinical trials in India.

14 Oct 2014

Sanofi French head Lajoux to leave at end-2014

PARIS - Sanofi's head of France, Christian Lajoux, plans to leave at the end of the year after 21 years with the drug making company, Chief Executive Chris Viehbacher said in a message to staff.

02 Oct 2014

Earnings vs. Estimates

Search Stocks